Search Results

GPCR collaboration at Monash shows how shared lab ecosystems can reshape innovation and accelerate drug discovery.

Next Recent Articles Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism Drug discovery often assumes receptor inhibition follows simple rules—agonist binds, antagonist blocks, and GPCR Podcast 4 days ago Molecular creativity in drug discovery Most pharmacologists are trained to chase

Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology . He is the inventor of OB-002 as well as the key technology underlying Orion’s discovery platform.

Published on July 4, 2025 Category GPCR Weekly News Stronger pharmacology drives smarter decisions in GPCR discovery Elevate your drug discovery program with 45+ lessons yearly.

✳️ Read the Weekly News → https://www.ecosystem.drgpcr.com/post/crush-data-confusion-conquer-gpcr-drug-discovery

GPCR Ecosystem We unite the GPCR Community to advance drug discovery Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools leaders, contributing behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by

scientists to go beyond explaining data — and start predicting the future of receptor function and drug discovery. News → ep 175 with jens carlsson clip 3 AI is changing how we think about structure, function, and discovery GPCR Podcast AI is changing how we think about structure, function, and discovery — but Jens Carlsson

How disease can hijack signaling organization — and what that means for drug discovery.

opportunities to connect, share, form trusting partnerships, grow, and thrive together to accelerate GPCR drug discovery and improve human health.

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and

Brian Arey About this episode Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular , biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems He continues to pioneer in drug discovery studying GPCRs and other target classes.

Brian Arey About this episode Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular , biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems He continues to pioneer in drug discovery studying GPCRs and other target classes.

discovery. and Arthur discussed Arthur's career journey in pharmacology, including his mentors and significant discoveries Arthur highlighted his mentors' influence, such as Fred Mitchelson and Nigel Burch, and significant discoveries discovery. Allosteric Modulation and Drug Discovery Yamina and Arthur delved into the complexities of protein-protein

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based drug Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience discovery research leading teams in West Point, Boston, and London at MSD.

Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing Yamina Berchiche 🔒 Premium Content Watch recording Applying Pharmacology to Drug Discovery Class 1 - Discovery II Advanced Methods for the Optimization of Candidate Selection Lecture 1: The Eyes to See Discovery I Techniques for Effective Lead Optimization of Candidate Molecules Lecture 1: GPCR Project Initiation and Design for Discovery of New Molecules Lecture 2: Drug Affinity: Measurement of Antagonism

interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the

Join Terry’s Corner AMA to master GPCR signaling, allosteric modulation, and kinetic strategy in drug discovery. In the discovery phase, one overlooked kinetic parameter or a misjudged model can set your team back It’s 45+ years of applied discovery experience from Terry Kenakin distilled into practical, modular lessons Don’t fall behind on what will shape the next decade of discovery.

University before continuing her training as a postdoctoral fellow at the Vanderbilt Center for Neuroscience Drug Discovery, the National Institute of General Medical Sciences, and the National Institute on Alcohol

His interests are in receptor pharmacology, allosteric protein function, and drug discovery. Dr.

receptors involved in many, if not all, physiological responses, with the ultimate goal of improving drug in-cellulo measurement of protein-protein interactions, receptor trafficking and signalling, useful for drug discovery programs.

advisory is built on principles that ensure clarity, minimize risk, and drive enduring results in GPCR drug discovery. Berchiche, and I understand the intricate challenges of GPCR drug discovery. connect you with critical insights and key collaborators, further accelerating your progress in GPCR drug discovery.

Stay current in drug discovery with the University Vault. Anonymous This looks super useful for drug discovery!

he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery

Aurélien Rizk is a scientist and entrepreneur in drug discovery. Before focusing on the development of innovative mathematical modeling and simulation methods for drug discovery, Dr. Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery Aurelien Rizk confirmed his attendance at the upcoming GPCR-Targeted Drug Discovery Summit in Boston.

Happy Hours GPCR Happy Hour – Boston, Sept 2025 Every September, Boston welcomes the global biotech and drug discovery community.

Receptor Biology at the University of Copenhagen where he leads a research cluster for GPCR function and drug discovery and a Pharmaceutical Data Science unit. one of the coordinators of recommendations to describe ligand bias towards signaling probes and safer drugs

studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases.

Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets

cell signaling and GPCRs and made seminal contributions to our understanding of this major class of drug energy transfer (BRET) resulted in the development of screening assays that are now widely used for drug discovery.

studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases.